Misvik Biology

27/08/2021

HER2 has been shown to be expressed in up to 50% of ductal salivary gland cancers and up to 25% of all salivary gland cancers. Targeted therapies are available and they work. Yet, the national treatment guidelines in Finland and many other countries still rely solely on the unspecific cytotoxic drugs and do not consider HER2 as a therapy target in these cancers. Based on accumulating evidence, these patients should be treated based on the molecular characteristics of the tumors. Stay tuned for our full paper at Frontiers in Oncology: https://www.frontiersin.org/articles/10.3389/fonc.2021.735820/abstract

11/05/2021

Even some of the most rare cancers in the world can be caused by well known cancer susceptibility genes, and there could be targeted therapies available. Read our study of DNA repair targeting in an extreme rare cutaneous apocrine carcinoma associated with a Finnish founder mutation on PALB2. https://doi.org/10.18632/oncotarget.27961

18/04/2021

Interested in tailor made peptidyl diphenyl phosphonate warheads for analysis of proteolytic networks? Check out our latest collaborative study published in Nature Chemical Biology revealing the proteolytic regulatory network of CDCP1, a potent therapeutic target across multiple human cancers. Read the full article from here:

A substrate-biased activity-based probe technology was developed to enable relatively facile identification of proteases responsible for specific proteolytic events in complex biological milieu, revealing that urokinase regulates CDCP1 proteolysis.

25/02/2021

Small but mighty! According to the latest H2020 country statistics, Misvik is ranked second among all Finnish life science, pharma and biotech companies in the number of participation to EC funded research and innovation projects!

08/12/2020

Scientific discoveries from small Finnish biotechs are not frequently published in Cell! In fact this could be a first! Stay tuned for a new target to overcome resistance to I-O checkpoint inhibition!! Wohoo IF38!! 🥂

07/12/2020

What an inspirational day at the lab putting together the Prusa Research i3 printer kit! Let the 3D printing begin!

27/10/2020

Amazing news!! European Commission awards 20M€ for the H2020 Research and Innovation project PrecisionTox to develop New Approach Methodologies for Chemical Safety to transform environmental health protection! Congratulations to our coordinator John Colbourne and the whole consortium!

20/10/2020

Introduction to the cancer expertise in Finland: https://www.magnetcloud1.eu/b/businessfinland/CancerExpertiseFromFinland/ =1

27/08/2020

Protect our sea! 27.8. Baltic Sea Day

19/08/2020

Happy for the possibility to support the next generation of research talents! Biotechnology Engineering student Emma Talvitie is completing her Masters (Tech.) at Misvik working on convolutional neural network models for analysis of organoid microarrays for immuno-oncology and drug development.

07/07/2020

For rare cancers, n-of-1 style studies may be the only approach to demonstrate novel treatment options. In our latest study published today at Neoplasia we use multiomics methods for ex vivo modelling of drug efficacy and personalized treatment in an extreme rare epithelial-myoepithelial salivary gland cancer. Study the full article at https://www.sciencedirect.com/science/article/pii/S1476558620301299

06/07/2020

Fresh from the press! Parallel ex vivo modelling of therapy efficacy on tumor and malignant ascites in rare Krukenberg tumor identifies VEGFR-TKI mediated targeting of immunosuppressive tumor associated macrophages.

https://www.sciencerepository.org/ex-vivo-modelling-of-therapy-efficacy-for-rare-krukenberg-tumors_COR-2020-7-101